▶ Full Post Text
Disclosure: Recently bought a small position (sub 10K) based off some light weight research
Simply Good Foods ($SMPL) the company behind Quest protein bars and Atkins shakes is one of the more interesting setups I've come across while digging through SEC filings in last couple of days. I see other people have posted about this here in recent past and that they hold positions.
**The story:**
CEO Geoff Tanner was removed on Jan 18, 2026. The very next day, **Joseph Scalzo** - the founder who took the company public in 2017 and led the Quest Nutrition acquisition - returned as CEO. His compensation: $1.1M salary + **2 million stock options** at current prices. That's a bet-on-yourself package.
**Who bought:**
Before the CEO change was announced, two C-suite insiders bought stock with their own money (not grants - open market purchases):
| Insider | Role | Shares | Price | Total | Date |
|---------|------|--------|-------|-------|------|
| Christopher Bealer | CFO | 9,946 | $20.01 | **$199,019** | Nov 6, 2025 |
| Michael Clawson | CCO | 5,000 | $20.00 | **$100,000** | Nov 17, 2025 |
These buys came right after the 10-K filing (Oct 28). They had full visibility into the financials. The CEO exit was likely already in the works.
Then on Feb 3, 2026 - two weeks after the CEO switch - **Rep. Tim Moore (R-NC)** bought $15,001-$50,000 worth of SMPL.
Moore is worth paying attention to because his trading pattern is consistent - he's a value/contrarian trader who buys beaten-down American brands. His recent buys: **Harley-Davidson** (8 separate purchases), **Krispy Kreme** (3 purchases), **Cracker Barrel**, **Intel**, **Verizon**, **American Airlines** - all bought during dips. He bought AAL multiple times and sold for profit. Same with HOG and CBRL. He also bought DNUT on Feb 12, 9 days after SMPL. This isn't a random one-off - SMPL fits his playbook exactly: iconic consumer brand, hammered stock, value entry point.
**The numbers (from 10-K):**
| Metric | Value |
|--------|-------|
| Revenue | $1.45B |
| Net income | $103.6M |
| Gross margin | 36% (annual), 32.3% (latest quarter) |
| Operating cash flow | $178M |
| P/E (trailing) | ~19x |
| P/E (forward) | **~8x** |
| Stock price | $17.05 |
| 52-week high | $38.16 |
| Analyst target (mean) | **$28.00** (10 analysts) |
| Analyst target range | $20 - $39 |
| Options put/call | 0.36 (bullish) |
| Insider ownership | 8.76% |
The stock is down 55% from its 52-week high. Forward P/E of 8x on a profitable, cash-generating business.
**What the filings flagged:**
1. **Customer concentration**: Walmart is 31% of sales, Amazon is 18%. ~50% of revenue from two customers.
2. **New risk factor**: GLP-1 weight-loss drugs (Ozempic/Wegovy). Management explicitly flagged this as a threat to protein snack demand. That's honest disclosure - and it's the main reason the stock tanked.
3. **Clean forensics**: No channel stuffing signals, no DSO bloat, no going concern language, no material weaknesses.
4. **Returning CEO with 2M options**: Scalzo's compensation is mostly upside. His options are worth nothing unless the stock recovers.
**Bull case:** Founder CEO back with skin in the game. CFO and CCO bought at $20 with their own cash. Congressman bought after the leadership change. Forward P/E of 8x. Analysts say $28. Business is profitable and generating $178M in cash flow. $500M buyback authorization - management putting cash where their mouth is. Market is overreacting to GLP-1 fears.
**Bear case:** Q1 FY2026 earnings missed - EPS $0.26 vs $0.36 estimate. Gross margin dropped 590 basis points to 32.3% due to cocoa costs and tariffs. Adjusted EBITDA fell 20.6%. $60.9M non-cash impairment on the Atkins brand. Some analysts downgraded to Hold. GLP-1 drugs could genuinely shrink protein snack demand long-term. Stock went from $38 to $17 for a reason. 50% of revenue concentrated in Walmart + Amazon. Insiders bought at $20 and are underwater. Scalzo is 66 - this is a bridge CEO, not a growth story.
**The key question:** Does ones believe Ozempic will destroy the protein snacking market? That's the entire thesis in one sentence. The insider and congress buying says "the market is overreacting." The GLP-1 trend says "maybe not." and I have asked this question here few days ago and people generally had a view that GLP-1 isn't as big of a threat as it is made out to be.
**Not financial advice.**